CEL-SCI Corporation (NYSE:CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results